Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 19/20 | 0.41 |
| ▸ | PGR | P06401 | 2/20 | 0.37 |
| ▸ | CFTR | P13569 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24524549 | 0.93 | AR (0.41) | ARPGR | |
| SCHEMBL1259671 | 0.84 | AR (0.46) | ARPGR | |
| SCHEMBL203731 | 0.82 | AR (0.44) | ARPGR | |
| SCHEMBL12495047 | 0.79 | TRPV4 (0.42) | ARPGR | |
| SCHEMBL29502009 | 0.78 | AR (0.41) | ARPGR | |
| SCHEMBL4025318 | 0.78 | AR (0.41) | ARPGR | |
| SCHEMBL324217 | 0.78 | AR (0.47) | ARPGR | |
| SCHEMBL22366874 | 0.78 | AR (0.46) | ARPGR | |
| SCHEMBL23899010 | 0.78 | AR (0.47) | ARPGR | |
| SCHEMBL202518 | 0.78 | AR (0.46) | ARPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240166624-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | FLARE THERAPEUTICS INC. | 2024-05-23 | — | — | US | disclosed |
| CN-117616012-A | PPARG inverse agonists and uses thereof | 弗拉雷治疗公司 | 2024-02-27 | — | — | CN | disclosed |
| EP-4301734-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | Flare Therapeutics Inc. (US) | 2024-01-10 | — | — | EP | disclosed |
| US-11648234-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2023-05-16 | — | — | US | disclosed |
| WO-2022187203-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | FLARE THERAPEUTICS, INC. (US) | 2022-09-09 | — | — | WO | disclosed |
| EP-3976577-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | University of Tennessee Research Foundation (US) | 2022-04-06 | — | — | EP | disclosed |
| US-20220081401-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2022-03-17 | — | — | US | disclosed |
| US-20220081401-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2022-03-17 | — | — | US | disclosed |
| US-11230523-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2022-01-25 | — | — | US | disclosed |
| US-11230523-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2022-01-25 | — | — | US | disclosed |
| EP-1756109-A1 | NOVEL INDOLE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-28 | — | — | EP | disclosed |
| EP-1753749-A1 | NOVEL INDOLE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-21 | — | — | EP | disclosed |
| US-20060211756-A1 | Novel heterocycle derivatives useful as selective androgen receptor modulators (SARMs) | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-09-21 | — | — | US | disclosed |
| WO-2006055184-A2 | NOVEL HETEROCYCLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-26 | — | — | WO | disclosed |
| WO-2005110985-A2 | INDOLE, BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-11-24 | — | — | WO | disclosed |
| WO-2005111042-A1 | NOVEL INDOLE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-11-24 | — | — | WO | disclosed |
| WO-2005111028-A1 | NOVEL INDOLE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-11-24 | — | — | WO | disclosed |
| US-20050250740-A1 | Novel indole derivatives as selective androgen receptor modulator (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-11-10 | — | — | US | disclosed |
| US-20050250741-A1 | non-steroidal agonists and antagonists; 2-(2-ethylsulfanyl-1-hydroxy-1-methyl-ethyl)-6-trifluoromethyl-1H-indole-5--carbonitrile; anticarcinogenic; prostate carcinoma, benign prostatic hyperplasia (BPH), hirsutism, alopecia, anorexia nervosa, breast cancer, acne, AIDS, cachexia, as a male contraceptive | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-11-10 | — | — | US | disclosed |
| US-20050245485-A1 | Novel indole derivatives as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240166624-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | PPARG, PPARA, PPARD | AR 153/4885PGR 130/4885CFTR 110/4885 |
| US-11230523-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | AR, BRCA1, AHR | AR 1/4885PGR 24/4885CFTR 2820/4885 |
| US-20220081401-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | AR, BRCA1, AHR | AR 1/4885PGR 24/4885CFTR 2820/4885 |
| US-20050250741-A1 | non-steroidal agonists and antagonists; 2-(2-ethylsulfanyl-1-hydroxy-1-methyl-ethyl)-6-trifluoromethyl-1H-indole-5--carbonitrile; anticarcinogenic; prostate carcinoma, benign prostatic hyperplasia (BPH), hirsutism, alopecia, anorexia nervosa, breast cancer, acne, AIDS, cachexia, as a male contraceptive | AR, NR5A1, FSHR | AR 1/4885PGR 14/4885CFTR 2232/4885 |
| US-20060211756-A1 | Novel heterocycle derivatives useful as selective androgen receptor modulators (SARMs) | AR, NR5A1, NR5A2 | AR 1/4885PGR 61/4885CFTR 3185/4885 |
| US-11648234-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use | AR, BRCA1, FSHR | AR 1/4885PGR 115/4885CFTR 3423/4885 |
| US-20050245485-A1 | Novel indole derivatives as selective androgen receptor modulators (SARMS) | AR, NR5A1, NR5A2 | AR 1/4885PGR 134/4885CFTR 3990/4885 |
| US-20050250740-A1 | Novel indole derivatives as selective androgen receptor modulator (SARMS) | AR, NR5A1, NR5A2 | AR 1/4885PGR 136/4885CFTR 3962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.